Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies

Morikawa, Miyuki; Kuwahara, Motoi; Ueno, Rino; Samukawa, Makoto; Hamada, Yukihiro; Kusunoki, Susumu

doi:10.1016/j.jneuroim.2016.10.010

Cited by 23 publications

(20 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, anti-GM1 IgM antibodies have been detected in only one of four previously reported cases of childhood-onset MMN ( Table 2). On the other hand, anti-GalNAc-GD1a IgM antibodies have been detected in 20.8% of patients with adult-onset MMN [8]. As anti-GM2 IgM antibodies are also significantly associated with MMN [9], comprehensive testing for serum anti-glycolipid antibodies in addition to GM1 may aid in the diagnosis of childhood-onset MMN.…”

Section: Discussionmentioning

confidence: 99%

Childhood-onset multifocal motor neuropathy with IgM antibodies to GM2 and GalNac-GD1a

Maéda

Ishii

Kusunoki

et al. 2020

Brain and Development

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Childhood-onset multifocal motor neuropathy with IgM antibodies to GM2 and GalNac-GD1a

Maéda

Ishii

Kusunoki

et al. 2020

Brain and Development

Self Cite

View full text Add to dashboard Cite

“…Rinaldi et al and Galban‐Horcajo et al recently examined numerous combinations of glycolipid complexes in GBS and MMN using the glycoarray method: a comprehensive assay of glycolipids and glycolipid complexes antibodies, and IgM antibody to GM1/Gal‐C was identified as the most common antibody in patients with MMN . Using the same assay, we investigated the comparison of IgM and IgG antibodies with 55 antigens, including 10 glycolipids and 45 glycolipid complexes comprising of their combinations in immune‐mediated neuropathies . GalNAc‐GD1a‐related IgM antibodies (antibodies to GalNAc‐GD1a or glycolipid complexes comprising GalNAc‐GD1a and another glycolipid) were detected in 37.5% (9/24) of MMN, whereas GM1‐related IgM antibodies were detected in 50% (12/24) of MMN.…”

Section: Glycolipid Antibodies In Chronic Inflammatory Demyelinating mentioning

confidence: 99%

“…[80][81][82] Using the same assay, we investigated the comparison of IgM and IgG antibodies with 55 antigens, including 10 glycolipids and 45 glycolipid complexes comprising of their combinations in immune-mediated neuropathies. 83 GalNAc-GD1a-related IgM antibodies (antibodies to GalNAc-GD1a or glycolipid complexes comprising GalNAc-GD1a and another glycolipid) were detected in 37.5% (9/24) of MMN, whereas GM1-related IgM antibodies were detected in 50% (12/24) of MMN. Therefore not only GM1, but also GalNAc-GD1a is an important target antigen in MMN.…”

Section: Other Glycolipid Antibodiesmentioning

confidence: 99%

Mechanism and spectrum of anti‐glycolipid antibody‐mediated chronic inflammatory demyelinating polyneuropathy

Kuwahara

Kusunoki

2018

Clinical & Exp Neuroim

Self Cite

View full text Add to dashboard Cite

The pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP) is composed of cellular and humoral immunities. Macrophages might play a crucial role in cellular immunity. In addition, autoantibodies participate in the pathogenesis of CIDP. To date, various autoantibodies have been reported to affect peripheral nerve myelin. Although antibodies to glycolipids are frequently identified in Guillain‐Barré syndrome and closely related to the development of neuropathies, these are detected in only a small percentage of CIDP instances. Among glycolipids, sialosylneolactotetraosylceramide (LM1) is predominantly localized in human peripheral nerve myelin. LM1‐related antibodies (e.g. anti‐LM1, GM1/LM1 and GD1b/LM1 antibodies) are detected in some patients with CIDP and Guillain‐Barré syndrome. CIDP patients with those antibodies frequently present ataxia, but rarely have cranial nerve deficits; these features are associated with the localization of LM1, which is more abundant in the dorsal root than the cranial nerves. In immunoglobulin M paraproteinemic neuropathies, except for the anti‐myelin‐associated glycoprotein neuropathies, antibodies to glycolipids with disialosyl residues, such as GD1b and GQ1b, are also detected on occasion. Notably, this feature is clinically characterized by chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M paraprotein, cold agglutinins and disialosyl antibodies. Such clinical features are related to the localization of GD1b or GQ1b in human peripheral nerves. Overall, these correlations suggest a direct involvement of the antibodies in the pathogenesis of those aforementioned neuropathies.

show abstract

“…In MS, anti-sulfatide antibodies have been found in cerebrospinal fluid, suggesting local intrathecal synthesis by ectopic B cells ( Brennan et al, 2011 ; Ilyas et al, 2003 ; Kanter et al, 2006 ). In cohorts of GBS and other autoimmune neuropathy cases, serum anti-sulfatide antibodies have been reported with varying sensitivity and specificity ( Fredman et al, 1991 ; Halstead et al, 2016 ; Ilyas et al, 1991 ; Morikawa et al, 2016 ; Petratos et al, 1999 ; Rinaldi et al, 2013 ; Terryberry et al, 1995 ). Antibodies binding to sulfatide have been predominantly linked with demyelinating neuropathies, consistent with the abundance of the glycolipid in myelin, but have also been associated with neuropathies characterised by prominent axonal loss ( Carpo et al, 2000 ).…”

Section: Introductionmentioning

confidence: 99%

Differential binding patterns of anti-sulfatide antibodies to glial membranes

Meehan

McGonigal

Cunningham

et al. 2018

Journal of Neuroimmunology

View full text Add to dashboard Cite

Sulfatide is a major glycosphingolipid in myelin and a target for autoantibodies in autoimmune neuropathies. However neuropathy disease models have not been widely established, in part because currently available monoclonal antibodies to sulfatide may not represent the diversity of anti-sulfatide antibody binding patterns found in neuropathy patients. We sought to address this issue by generating and characterising a panel of new anti-sulfatide monoclonal antibodies. These antibodies have sulfatide reactivity distinct from existing antibodies in assays and in binding to peripheral nerve tissues and can be used to provide insights into the pathophysiological roles of anti-sulfatide antibodies in demyelinating neuropathies.

show abstract

Serological study using glycoarray for detecting antibodies to glycolipids and glycolipid complexes in immune-mediated neuropathies

Cited by 23 publications

References 23 publications

Childhood-onset multifocal motor neuropathy with IgM antibodies to GM2 and GalNac-GD1a

Childhood-onset multifocal motor neuropathy with IgM antibodies to GM2 and GalNac-GD1a

Mechanism and spectrum of anti‐glycolipid antibody‐mediated chronic inflammatory demyelinating polyneuropathy

Differential binding patterns of anti-sulfatide antibodies to glial membranes

Contact Info

Product

Resources

About